215 related articles for article (PubMed ID: 29549945)
1. Targeted transport of nanocarriers into brain for theranosis with rabies virus glycoprotein-derived peptide.
Fu C; Xiang Y; Li X; Fu A
Mater Sci Eng C Mater Biol Appl; 2018 Jun; 87():155-166. PubMed ID: 29549945
[TBL] [Abstract][Full Text] [Related]
2. Enhanced BBB permeability of osmotically active poly(mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer's disease.
Park TE; Singh B; Li H; Lee JY; Kang SK; Choi YJ; Cho CS
Biomaterials; 2015 Jan; 38():61-71. PubMed ID: 25457984
[TBL] [Abstract][Full Text] [Related]
3. A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA.
Hwang DW; Son S; Jang J; Youn H; Lee S; Lee D; Lee YS; Jeong JM; Kim WJ; Lee DS
Biomaterials; 2011 Jul; 32(21):4968-75. PubMed ID: 21489620
[TBL] [Abstract][Full Text] [Related]
4. The potential use of rabies virus glycoprotein-derived peptides to facilitate drug delivery into the central nervous system: a mini review.
Huey R; Hawthorne S; McCarron P
J Drug Target; 2017 Jun; 25(5):379-385. PubMed ID: 27581650
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of proteins into the central nervous system mediated by rabies virus glycoprotein-derived peptide.
Fu A; Wang Y; Zhan L; Zhou R
Pharm Res; 2012 Jun; 29(6):1562-9. PubMed ID: 22231987
[TBL] [Abstract][Full Text] [Related]
6. Enhanced transport of plant-produced rabies single-chain antibody-RVG peptide fusion protein across an in cellulo blood-brain barrier device.
Phoolcharoen W; Prehaud C; van Dolleweerd CJ; Both L; da Costa A; Lafon M; Ma JK
Plant Biotechnol J; 2017 Oct; 15(10):1331-1339. PubMed ID: 28273388
[TBL] [Abstract][Full Text] [Related]
7. Brain-targeted delivery of protein using chitosan- and RVG peptide-conjugated, pluronic-based nano-carrier.
Kim JY; Choi WI; Kim YH; Tae G
Biomaterials; 2013 Jan; 34(4):1170-8. PubMed ID: 23122677
[TBL] [Abstract][Full Text] [Related]
8. In vivo biodistribution of prion- and GM1-targeted polymersomes following intravenous administration in mice.
Stojanov K; Georgieva JV; Brinkhuis RP; van Hest JC; Rutjes FP; Dierckx RA; de Vries EF; Zuhorn IS
Mol Pharm; 2012 Jun; 9(6):1620-7. PubMed ID: 22536790
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Central Nervous System (CNS): A Review of Rabies Virus-Targeting Strategies.
Oswald M; Geissler S; Goepferich A
Mol Pharm; 2017 Jul; 14(7):2177-2196. PubMed ID: 28514853
[TBL] [Abstract][Full Text] [Related]
10. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles.
Liu Y; Huang R; Han L; Ke W; Shao K; Ye L; Lou J; Jiang C
Biomaterials; 2009 Sep; 30(25):4195-202. PubMed ID: 19467700
[TBL] [Abstract][Full Text] [Related]
11. Optical Imaging and Gene Therapy with Neuroblastoma-Targeting Polymeric Nanoparticles for Potential Theranostic Applications.
Lee J; Jeong EJ; Lee YK; Kim K; Kwon IC; Lee KY
Small; 2016 Mar; 12(9):1201-11. PubMed ID: 26573885
[TBL] [Abstract][Full Text] [Related]
12. PEGylated nanocarriers: A promising tool for targeted delivery to the brain.
Gajbhiye KR; Pawar A; Mahadik KR; Gajbhiye V
Colloids Surf B Biointerfaces; 2020 Mar; 187():110770. PubMed ID: 31926790
[TBL] [Abstract][Full Text] [Related]
13. Modified cyclodextrin-based nanoparticles mediated delivery of siRNA for huntingtin gene silencing across an in vitro BBB model.
Mendonça MCP; Cronin MF; Cryan JF; O'Driscoll CM
Eur J Pharm Biopharm; 2021 Dec; 169():309-318. PubMed ID: 34793942
[TBL] [Abstract][Full Text] [Related]
14. Updated Progress of Nanocarrier-Based Intranasal Drug Delivery Systems for Treatment of Brain Diseases.
Fan Y; Chen M; Zhang J; Maincent P; Xia X; Wu W
Crit Rev Ther Drug Carrier Syst; 2018; 35(5):433-467. PubMed ID: 30317945
[TBL] [Abstract][Full Text] [Related]
15. Self-assembled amphiphilic core-shell nanocarriers in line with the modern strategies for brain delivery.
Elezaby RS; Gad HA; Metwally AA; Geneidi AS; Awad GA
J Control Release; 2017 Sep; 261():43-61. PubMed ID: 28648865
[TBL] [Abstract][Full Text] [Related]
16. Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases.
Anthony DP; Hegde M; Shetty SS; Rafic T; Mutalik S; Rao BSS
Life Sci; 2021 Jun; 274():119326. PubMed ID: 33711385
[TBL] [Abstract][Full Text] [Related]
17. Efficient neuronal targeting and transfection using RVG and transferrin-conjugated liposomes.
Dos Santos Rodrigues B; Arora S; Kanekiyo T; Singh J
Brain Res; 2020 May; 1734():146738. PubMed ID: 32081534
[TBL] [Abstract][Full Text] [Related]
18. Ligand-Appended BBB-Targeted Nanocarriers (LABTNs).
Jain A; Jain SK
Crit Rev Ther Drug Carrier Syst; 2015; 32(2):149-80. PubMed ID: 25955883
[TBL] [Abstract][Full Text] [Related]
19. Targeting central nervous system pathologies with nanomedicines.
Mizrahy S; Gutkin A; Decuzzi P; Peer D
J Drug Target; 2019; 27(5-6):542-554. PubMed ID: 30296187
[TBL] [Abstract][Full Text] [Related]
20. Current Strategies for Brain Drug Delivery.
Dong X
Theranostics; 2018; 8(6):1481-1493. PubMed ID: 29556336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
